Subscribe
shutterstock_690219232
Katherine Welles / Shutterstock.com
22 May 2019Americas

Merck boosts oncology pipeline with $1bn deal

Merck has announced plans to acquire Peloton Therapeutics, a clinical-stage biopharmaceutical company, in a $1.05 billion bid to boost its oncology pipeline.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Fed Circuit sides with Merck in antifungal treatment dispute
25 June 2019   A US court has upheld a decision that eight claims of one of Mayne Pharma’s patents are unpatentable for obviousness over prior art after a validity challenge was brought by a subsidiary of Merck & Co.
Americas
Merck strengthens immunotherapy expertise with $773m buy
11 June 2019   US-based Merck & Co has announced plans to buy Tilos Therapeutics, its latest acquisition in the immunotherapy space.
Americas
Merck to buy immunotherapy company for $300m
26 February 2019   US-based Merck & Co has announced plans to acquire immunotherapy company Immune Design for $300 million, in a bid to strengthen its capabilities in vaccine development.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
Fed Circuit sides with Merck in antifungal treatment dispute
25 June 2019   A US court has upheld a decision that eight claims of one of Mayne Pharma’s patents are unpatentable for obviousness over prior art after a validity challenge was brought by a subsidiary of Merck & Co.
Americas
Merck strengthens immunotherapy expertise with $773m buy
11 June 2019   US-based Merck & Co has announced plans to buy Tilos Therapeutics, its latest acquisition in the immunotherapy space.
Americas
Merck to buy immunotherapy company for $300m
26 February 2019   US-based Merck & Co has announced plans to acquire immunotherapy company Immune Design for $300 million, in a bid to strengthen its capabilities in vaccine development.

More on this story

Big Pharma
Fed Circuit sides with Merck in antifungal treatment dispute
25 June 2019   A US court has upheld a decision that eight claims of one of Mayne Pharma’s patents are unpatentable for obviousness over prior art after a validity challenge was brought by a subsidiary of Merck & Co.
Americas
Merck strengthens immunotherapy expertise with $773m buy
11 June 2019   US-based Merck & Co has announced plans to buy Tilos Therapeutics, its latest acquisition in the immunotherapy space.
Americas
Merck to buy immunotherapy company for $300m
26 February 2019   US-based Merck & Co has announced plans to acquire immunotherapy company Immune Design for $300 million, in a bid to strengthen its capabilities in vaccine development.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB